PL2234617T3 - Schemat dawkowania związany z długodziałającymi estrami paliperydonu do wstrzykiwań - Google Patents

Schemat dawkowania związany z długodziałającymi estrami paliperydonu do wstrzykiwań

Info

Publication number
PL2234617T3
PL2234617T3 PL08863534T PL08863534T PL2234617T3 PL 2234617 T3 PL2234617 T3 PL 2234617T3 PL 08863534 T PL08863534 T PL 08863534T PL 08863534 T PL08863534 T PL 08863534T PL 2234617 T3 PL2234617 T3 PL 2234617T3
Authority
PL
Poland
Prior art keywords
estrams
long
acting injectable
dosing scheme
injectable paliperidone
Prior art date
Application number
PL08863534T
Other languages
English (en)
Inventor
An Margriet Cornelia Vermeulen
Alfons Jeanne Wouters
Srihari Gopal
Vivek KUSAMAKER
Peter H. Lewyn-Briscoe
Mahesh Samtani
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40428256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2234617(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL2234617T3 publication Critical patent/PL2234617T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10F—INORGANIC SEMICONDUCTOR DEVICES SENSITIVE TO INFRARED RADIATION, LIGHT, ELECTROMAGNETIC RADIATION OF SHORTER WAVELENGTH OR CORPUSCULAR RADIATION
    • H10F30/00—Individual radiation-sensitive semiconductor devices in which radiation controls the flow of current through the devices, e.g. photodetectors
    • H10F30/20—Individual radiation-sensitive semiconductor devices in which radiation controls the flow of current through the devices, e.g. photodetectors the devices having potential barriers, e.g. phototransistors
    • H10F30/21—Individual radiation-sensitive semiconductor devices in which radiation controls the flow of current through the devices, e.g. photodetectors the devices having potential barriers, e.g. phototransistors the devices being sensitive to infrared, visible or ultraviolet radiation
    • H10F30/22—Individual radiation-sensitive semiconductor devices in which radiation controls the flow of current through the devices, e.g. photodetectors the devices having potential barriers, e.g. phototransistors the devices being sensitive to infrared, visible or ultraviolet radiation the devices having only one potential barrier, e.g. photodiodes
    • H10F30/222—Individual radiation-sensitive semiconductor devices in which radiation controls the flow of current through the devices, e.g. photodetectors the devices having potential barriers, e.g. phototransistors the devices being sensitive to infrared, visible or ultraviolet radiation the devices having only one potential barrier, e.g. photodiodes the potential barrier being a PN heterojunction
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10P—GENERIC PROCESSES OR APPARATUS FOR THE MANUFACTURE OR TREATMENT OF DEVICES COVERED BY CLASS H10
    • H10P95/00—Generic processes or apparatus for manufacture or treatments not covered by the other groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Manufacturing & Machinery (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL08863534T 2007-12-19 2008-12-17 Schemat dawkowania związany z długodziałającymi estrami paliperydonu do wstrzykiwań PL2234617T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1491807P 2007-12-19 2007-12-19
US12027608P 2008-12-05 2008-12-05
EP08863534.7A EP2234617B2 (en) 2007-12-19 2008-12-17 Dosing regimen associated with long acting injectable paliperidone esters
PCT/EP2008/067738 WO2009080651A1 (en) 2007-12-19 2008-12-17 Dosing regimen associated with long acting injectable paliperidone esters

Publications (1)

Publication Number Publication Date
PL2234617T3 true PL2234617T3 (pl) 2021-11-08

Family

ID=40428256

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08863534T PL2234617T3 (pl) 2007-12-19 2008-12-17 Schemat dawkowania związany z długodziałającymi estrami paliperydonu do wstrzykiwań

Country Status (28)

Country Link
US (3) US9439906B2 (pl)
EP (2) EP2234617B2 (pl)
JP (1) JP5825786B2 (pl)
KR (3) KR20100099292A (pl)
CN (2) CN101932327A (pl)
AU (2) AU2008340101C1 (pl)
BR (1) BRPI0821408A2 (pl)
CO (1) CO6300949A2 (pl)
CY (1) CY1124103T1 (pl)
DK (1) DK2234617T4 (pl)
EA (1) EA020697B1 (pl)
EC (1) ECSP10010289A (pl)
ES (1) ES2868353T5 (pl)
FI (1) FI2234617T4 (pl)
GT (1) GT201000182A (pl)
HK (1) HK1223850A1 (pl)
HR (1) HRP20210669T4 (pl)
HU (1) HUE053904T2 (pl)
IL (2) IL206448A (pl)
LT (1) LT2234617T (pl)
MY (1) MY204500A (pl)
NI (1) NI201000105A (pl)
NZ (1) NZ586221A (pl)
PL (1) PL2234617T3 (pl)
PT (1) PT2234617T (pl)
RS (1) RS61765B2 (pl)
SI (1) SI2234617T2 (pl)
WO (1) WO2009080651A1 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
KR20100099292A (ko) 2007-12-19 2010-09-10 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
EP2485767A1 (en) * 2009-10-06 2012-08-15 Ascendis Pharma A/S Carrier linked paliperidone prodrugs
AU2010313290A1 (en) 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
EP2547206B1 (en) 2010-03-15 2016-05-11 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
US9522980B2 (en) 2010-05-06 2016-12-20 Johnson & Johnson Vision Care, Inc. Non-reactive, hydrophilic polymers having terminal siloxanes and methods for making and using the same
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
MX358344B (es) * 2011-03-18 2018-08-15 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas que comprenden un antipsicotico insoluble en agua y esteres de sorbitan.
US9170349B2 (en) 2011-05-04 2015-10-27 Johnson & Johnson Vision Care, Inc. Medical devices having homogeneous charge density and methods for making same
PT2529757E (pt) 2011-05-31 2014-02-27 Rovi Lab Farmaceut Sa Formulação para implante de paliperidona
ES2878112T3 (es) 2011-05-31 2021-11-18 Farm Rovi Lab Sa Formulación de implante de risperidona y/o paliperidona
CN102274164B (zh) * 2011-08-22 2014-07-02 长春健欣生物医药科技开发有限公司 帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂
CN103301461B (zh) * 2012-03-08 2018-09-07 江苏豪森药业集团有限公司 一种长效注射制剂及其制备方法和用途
NZ630428A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
EP2827868B8 (en) 2012-03-19 2019-12-18 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
US10073192B2 (en) 2012-05-25 2018-09-11 Johnson & Johnson Vision Care, Inc. Polymers and nanogel materials and methods for making and using the same
US9244196B2 (en) 2012-05-25 2016-01-26 Johnson & Johnson Vision Care, Inc. Polymers and nanogel materials and methods for making and using the same
WO2014080285A2 (en) 2012-09-19 2014-05-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN110368360A (zh) 2014-03-20 2019-10-25 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
JP6591546B2 (ja) 2014-08-25 2019-10-16 アルカームス ファーマ アイルランド リミテッド 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
ES2870498T3 (es) 2015-02-17 2021-10-27 Vanda Pharmaceuticals Inc Iloperidona para el tratamiento de esquizofrenia
WO2016157061A1 (en) 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
SMT202000351T1 (it) * 2015-04-07 2020-09-10 Janssen Pharmaceuticals Inc Regime di dosaggio per dosi mancate per esteri di paliperidone iniettabili ad azione prolungata
WO2018098115A1 (en) * 2016-11-23 2018-05-31 Children's Hospital Medical Center Paliperidone for treatment of drug refractory irritability and autism spectrum disorder
US11666573B2 (en) 2017-10-27 2023-06-06 Geneora Pharma (Shijiazhuang) Co., Ltd. Dosage regimen of paliperidone palmitate extended-release injectable suspension
WO2019173230A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN110279659A (zh) * 2019-07-08 2019-09-27 华裕(无锡)制药有限公司 棕榈酸帕利哌酮制剂及其制备方法
GR1009869B (el) * 2019-07-12 2020-11-12 Φαρματεν Α.Β.Ε.Ε. Ενεσιμο παρατεταμενης αποδεσμευσης φαρμακευτικο σκευασμα που περιλαμβανει παλμιτικη παλιπεριδονη και μεθοδος παρασκευης αυτου
MX2022003646A (es) 2019-09-25 2022-07-12 Janssen Pharmaceuticals Inc Interconexión de sistemas de administración de fármaco.
WO2022006336A1 (en) * 2020-07-01 2022-01-06 Jubilant Pharma Holdings Inc. Long-acting injection dosage form of beta 3 adrenoreceptor agonists
EP4025189B1 (en) 2020-11-30 2024-06-05 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
MX2023006369A (es) 2020-11-30 2023-08-09 Janssen Pharmaceutica Nv Metodos para asegurar resuspension de formulaciones de palmitato de paliperidona.
WO2022111859A1 (en) 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
PL4025187T3 (pl) 2020-11-30 2024-04-29 Janssen Pharmaceutica Nv Schematy dawkowania związane z formulacjami paliperydonu do wstrzykiwania o przedłużonym uwalnianiu
RU2756614C1 (ru) * 2021-04-07 2021-10-04 Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) Способ поддержки принятия врачебных решений выбора антипсихотической терапии у больных шизофренией с целью профилактики акатизии
US12472184B2 (en) 2021-08-20 2025-11-18 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1491807A (en) 1922-06-20 1924-04-29 John P Mclinn Traveling bag
US1491809A (en) 1923-02-17 1924-04-29 Us Fireworks Mfg Company Inc Toy
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6342488B1 (en) * 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
KR100338776B1 (ko) 2000-07-11 2002-05-31 윤종용 멀티 로우 어드레스 테스트 가능한 반도체 메모리 장치 및그 테스트 방법
JP4500679B2 (ja) 2002-07-29 2010-07-14 アルザ・コーポレーシヨン パリペリドンを制御送達する方法および投薬形態物
AU2003265511A1 (en) 2002-08-21 2004-03-11 Pharmacia Corporation Injectable pharmaceutical suspension in a two-chamber vial
US20060079846A1 (en) 2004-10-08 2006-04-13 Alton Williams Hypodermic syringes with multiple needles and methods of calming psychiatric patients using such
US20080214808A1 (en) * 2005-04-25 2008-09-04 Thomas Frederik Ernestine Spittaels Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester
US20070197591A1 (en) * 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
US20070232624A1 (en) * 2006-04-03 2007-10-04 Palumbo Joseph M Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients
ES2304336T1 (es) 2006-08-14 2008-10-16 Teva Pharmaceutical Industries Ltd. Formas cristalinas de 9-hidroxi-risperidona (paliperidona).
PL2079446T3 (pl) 2007-08-21 2012-04-30 Teva Pharma Preparat paliperidonu o przedłużonym uwalnianiu
JP2010540676A (ja) 2007-10-09 2010-12-24 シプラ・リミテッド パリペリドン及びその医薬として許容し得る塩の製造方法、並びに該方法に使用する中間体
KR20100099292A (ko) 2007-12-19 2010-09-10 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
AU2010313290A1 (en) 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
US11114549B2 (en) 2017-11-29 2021-09-07 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor structure cutting process and structures formed thereby
US11450758B2 (en) 2020-06-12 2022-09-20 Taiwan Semiconductor Manufacturing Co., Ltd. Gate structure of semiconductor device and method of forming same

Also Published As

Publication number Publication date
JP5825786B2 (ja) 2015-12-02
WO2009080651A1 (en) 2009-07-02
CN105560176A (zh) 2016-05-11
KR102163196B1 (ko) 2020-10-12
NI201000105A (es) 2011-03-17
US20170128451A1 (en) 2017-05-11
RS61765B1 (sr) 2021-05-31
HK1223850A1 (zh) 2017-08-11
EP2234617B2 (en) 2024-11-06
PT2234617T (pt) 2021-05-18
KR20100099292A (ko) 2010-09-10
AU2008340101B2 (en) 2015-02-19
EA020697B1 (ru) 2015-01-30
KR20190049933A (ko) 2019-05-09
SI2234617T1 (sl) 2021-07-30
KR20170018489A (ko) 2017-02-17
GT201000182A (es) 2012-03-26
KR102318070B1 (ko) 2021-10-27
HUE053904T2 (hu) 2021-07-28
US20090163519A1 (en) 2009-06-25
HRP20210669T1 (hr) 2021-10-29
AU2008340101A1 (en) 2009-07-02
LT2234617T (lt) 2021-05-25
IL253468A0 (en) 2017-09-28
EP2234617A1 (en) 2010-10-06
IL206448A (en) 2017-12-31
JP2011506555A (ja) 2011-03-03
SI2234617T2 (sl) 2025-05-30
IL206448A0 (en) 2010-12-30
DK2234617T4 (da) 2024-12-16
DK2234617T3 (da) 2021-05-25
RS61765B2 (sr) 2025-01-31
US9439906B2 (en) 2016-09-13
NZ586221A (en) 2012-08-31
AU2008340101C1 (en) 2025-03-06
EA201070757A1 (ru) 2011-02-28
CO6300949A2 (es) 2011-07-21
EP2234617B1 (en) 2021-03-31
CY1124103T1 (el) 2022-05-27
EP3909585A1 (en) 2021-11-17
MY204500A (en) 2024-08-30
ECSP10010289A (es) 2010-07-30
ES2868353T3 (es) 2021-10-21
AU2015200801A1 (en) 2015-03-12
CN101932327A (zh) 2010-12-29
BRPI0821408A2 (pt) 2015-06-16
ES2868353T5 (en) 2025-04-02
US20180147210A1 (en) 2018-05-31
HRP20210669T4 (hr) 2024-12-06
FI2234617T4 (fi) 2024-12-23
AU2015200801B2 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
PL2234617T3 (pl) Schemat dawkowania związany z długodziałającymi estrami paliperydonu do wstrzykiwań
BR112012001988A2 (pt) composição de insulina de ação prolongada
BRPI0814426A2 (pt) Compostos heterocíclicos úteis como inibidores de mk2
DK2376490T3 (da) Imidazopyridinforbindelser
ATE539070T1 (de) Heterozyklische antivirale verbindungen
BRPI0916233A2 (pt) compostos heterocíclicos antivirais
DK2370460T3 (da) Glucagon analoger
BRPI0914657A2 (pt) piridin-2-onae piridazin-3-onas substituídas
BRPI0823379A2 (pt) Análogos de glucagon
BRPI0823377A2 (pt) análogos de glucagon
BRPI0823378A2 (pt) análogos de glucagon
BR112012005550A2 (pt) lactamas heterociclo-substituídas farmaceuticamente úteis
BR112012005616A2 (pt) compostos antivirais heterocíclicos
BRPI0905874A2 (pt) Composição fotoprotetora
DOP2011000086A (es) Derivados de acido 1-amino-2-ciclobutiletilboronico
BRPI1010852A2 (pt) compostos antivirais heterocíclicos
BRPI0906705A2 (pt) Composto heterocíclicos
HRP20150167T1 (xx) Spojevi kao antagonisti bradikinina-b1
ITFI20090031A1 (it) "blocco modulare per opere civili"
BRPI0924121A2 (pt) compostos antivirais heterocíclicos
BRPI1016266A2 (pt) compostos antivirais heterocíclicos
BR112012002336A2 (pt) compostos aza-heterocíclicos
DK2799428T3 (da) Glucagon-antagonister
HRP20150932T1 (xx) Heterocikliäśki spojevi
DK2427454T3 (da) Heterocykliske phenoxymethylforbindelser